A Study to Evaluate the Effect of Mild and Moderate Hepatic Impairment on the Single-Dose Pharmacokinetics of Rilzabrutinib (PRN1008)

NCT06444204 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

29

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatic Function Abnormal
Healthy Volunteers

Interventions

DRUG: Rilzabrutinib

Sponsor

Principia Biopharma, a Sanofi Company